Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00796900
Other study ID # EK 197/2004
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received November 20, 2008
Last updated May 11, 2011
Start date May 2008
Est. completion date March 2011

Study information

Verified date September 2009
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority Austria: Federal Ministry for Health Family and Youth
Study type Interventional

Clinical Trial Summary

Dantrolene is used to prevent hyperthermia in intensive care patients suffering from subarachnoidal hemorrhage.


Description:

Background:

Fever episodes occur in more than 50% of patients admitted to the ICU for subarachnoidal hemorrhage, central nervous system infection, seizure control, hemorrhagic stroke, and closed head injury despite antibiotic and antipyretic therapy.

The exact mechanism of hyperthermia-induced brain injury is not known; however, various processes may be involved. For example, hyperthermia might increase the release of excitatory neurotransmitter or trigger an abundant amount of oxygen free radicals. Hyperthermia may also aggravate blood-brain barrier disruption, impair cytoskeletal proteolysis, and/or enhance inhibition of enzymatic protein kinases, which, in turn, would impair recovery of energy metabolism. Antipyretics are effective for conventional fever, but less useful for various central hyperthermia syndromes, especially those resulting from strokes, SAH, and head injuries. Even aggressive cooling is usually insufficient in patients with fever because it is unable to overcome the high metabolic rate in these patients. Likewise, physical cooling is counteracted by the thermoregulatory defenses being activated to maintain hyperthermia. In non-sedated individuals, active cooling increases metabolic stress without decreasing core temperature at all. To date, treatment of centrally mediated hyperthermia remains unsatisfying.

Dantrolene has been available since 1975 as a specific treatment for acute malignant hyperthermia crises. However, dantrolene is increasingly being used for emergency treatment of life-threatening hyperthermia that is unresponsive to conventional treatments. For example, the drug has been used with some success for acute treatment of life-threatening hyperthermia resulting from neuroleptic malignant syndrome and hyperthermia associated with overdoses of various drugs. It has also been used for treatment of various other types of hyperthermia.

Efficacy in these cases appears to be based on a non-specific action of the drug; but to the extent dantrolene is effective, its action must conform to the laws of thermodynamics. Dantrolene must, therefore, reduce metabolic heat production, augment systemic heat loss, or alter the normal distribution of heat within the body. In other words, dantrolene must reverse the abnormal (or ineffective) thermoregulatory control that initiates the hyperthermic crises.

Item:

We propose to test the hypothesis that dantrolene will reduce centrally mediated fever in patients after subarachnoidal hemorrhage. Specifically, we will test the hypothesis that dantrolene decreases the magnitude and duration of hyperthermia.

The study will be restricted to neurosurgical patients with sustained fever (≥38ºC for more than an hour) without an identifiable infectious cause after subarachnoidal hemorrhage aged from 18 to 80 years. There will be no limitation of enrollment as to patients breathing spontaneously or being ventilator dependant.


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date March 2011
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- neurosurgical patients after subarachnoidal hemorrhage

- breathing spontaneously or being ventilator dependant

- sustained fever (=38ºC for more than an hour) without an identifiable infectious cause.

Exclusion Criteria:

- infection

- pregnancy

- arrhythmia

- muscular dystrophia

- acute liver disease

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Dantrolene
Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
Placebo
Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.

Locations

Country Name City State
Austria Medical University Vienna Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Magnitude and Duration of Hyperthermia 8 hours, every 10 minutes No
See also
  Status Clinical Trial Phase
Completed NCT04431596 - Military Alerting System for Monitoring Body Temperature During Active Cooling N/A
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT00940654 - The Fever and Antipyretic in Critically Illness Evaluation Study N/A
Active, not recruiting NCT05809453 - Intranasal Cocaine and Temperature Regulation During Exercise Phase 1/Phase 2
Completed NCT04915859 - Semiconductor Heat Extraction Cooling N/A
Completed NCT04613843 - Cold Water Immersion Stirring in Hyperthermic Individuals N/A
Completed NCT03689478 - Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT N/A
Completed NCT02271607 - The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients N/A
Terminated NCT01963117 - Effectiveness of the Combined WLI and Hyperthermia for GI Cancer Liver Metastasis N/A
Completed NCT04596618 - Impact of ICE on Exercise Performance in the Heat N/A
Withdrawn NCT05710978 - Biomarkers to Assess Acute Kidney Injury Risk During Heat Strain N/A
Completed NCT05586477 - Diphenhydramine and Sweating Phase 4
Completed NCT01576822 - Sauna Detoxification Study: Pilot Feasibility Phase 1
Recruiting NCT05366270 - Peripheral Neuroimmune Mechanisms of Hyperthermia N/A
Recruiting NCT05993910 - Prospective Hyperthermia Database in Cancer Patients (HT Register)
Terminated NCT04104334 - Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC N/A
Not yet recruiting NCT06389604 - Preparing for Heat Waves - Enhancing Human Thermophysiological Resilience N/A
Not yet recruiting NCT05274009 - Protective Cooling Measures to Safeguard Elderly People From Dangerous Summer Heat N/A
Active, not recruiting NCT02546596 - The Effect of Electro-Hyperthermia in Preoperative Radiotherapy for Locally Advanced Rectal Cancer N/A
Completed NCT05327764 - Work-To-Rest Ratios N/A